QNRX (Quoin Pharmaceuticals) מחיר לרווח עתידי

Quoin Pharmaceuticals (QNRX) maintains an impeccable reputation in the therapy of rare dermatoses. The company's forward P/E ratio visualizes this status, where the 0.00 mark indicates the level of investment risk. The brand attracts leading biochemists with generous RSU packages. High profitability is driven by the global sale of patented formulas with minimal production costs.
quoinpharma.com (QNRX) - פילוחי מדדים ודוחות פיננסיים

Quoin Pharmaceuticals (QNRX) focuses on therapies for ultra-rare dermatological diseases, which, combined with regular equity dilution, complicates profit forecasting. The forward P/E ratio relates the current share price to the expected net income for the following year; therefore, fluctuations in the company's projected P/E reflect the market's reassessment of risks associated with prolonged clinical trials and the volatility of the business's fundamental value.